FDA awards record number of review designations to ADCs in 2024
In 2024, the FDA granted a record 63 designations to antibody drug conjugates (ADCs), nearly double the previous high of 35 in 2023.
Drug Development
AstraZeneca to expand biomanufacturing in Maryland, US
Vaximm and BCME link on oral cancer immunotherapy platform
Alvotech and Advanz announce EC approval for Gobivaz biosimilar
Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership
Pfizer and Tris reach settlement with Texas over ADHD drug allegations
EC authorises Roche’s Lunsumio SC for follicular lymphoma
FDA approves AbbVie’s Epkinly to treat follicular lymphoma
